CALCULATE YOUR SIP RETURNS

Biocon Biologics Secures EC Approval For YESINTEK, Expanding Its European Markets Reach

Written by: Team Angel OneUpdated on: Feb 18, 2025, 3:14 PM IST
Biocon Biologics has received approval to sell YESINTEK in Europe. This medicine will help treat inflammatory diseases and provide a safe and effective option for patients.
Biocon Biologics Secures EC Approval For YESINTEK, Expanding Its European Markets Reach
ShareShare on 1Share on 2Share on 3Share on 4Share on 5

Biocon Biologics Ltd (BBL), a part of Biocon Ltd, has received marketing approval from the European Commission (EC) for its Ustekinumab biosimilar, YESINTEK. in Europe. This approval enables Biocon to distribute the drug across the European Union (EU), offering an alternative treatment for various inflammatory diseases.

YESINTEK: A New Treatment Option

YESINTEK is a medicine for adults and children with plaque psoriasis and for adults with psoriatic arthritis and Crohn’s disease. Tests have shown that it works just as well and is as safe as the original Ustekinumab drug, making it a good option for patients.

Strengthening Biocon’s Global Position

This milestone reinforces Biocon Biologics’ commitment to providing affordable and high-quality biosimilars worldwide. The company continues to expand its global footprint, leveraging its expertise in biosimilars to improve healthcare accessibility and offer cost-effective treatment options to patients in need.

About Biocon Biologics

Biocon Biologics Ltd is a global company specialising in biosimilars, offering affordable and high-quality medicines for various diseases. As a subsidiary of Biocon Ltd, it focuses on developing and supplying innovative treatments worldwide, improving healthcare access for patients.

Share Performance 

As of February 18, 2025, at 11:10 AM, the shares of Biocon are trading at ₹336.65 per share, down 3.14% from yesterday’s closing price. Over the last month, the stock has declined by 16.16% and over the last year it has fallen by 8.80%. The stock’s 52-week high is ₹404.70 and its low is ₹244.55.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Published on: Feb 18, 2025, 3:14 PM IST

Team Angel One

Team Angel One is a group of experienced financial writers that deliver insightful articles on the stock market, IPO, economy, personal finance, commodities and related categories.

Know More

We're Live on WhatsApp! Join our channel for market insights & updates

Open Free Demat Account!

Join our 3 Cr+ happy customers

+91
Enjoy Zero Brokerage on Equity Delivery
4.4 Cr+DOWNLOADS
Enjoy ₹0 Account Opening Charges

Get the link to download the App

Get it on Google PlayDownload on the App Store
Open Free Demat Account!
Join our 3 Cr+ happy customers